Cigna's Evernorth unit partners with rival Kaiser Permanente
Reuters
Published Apr 19, 2022 04:58PM ET
(Reuters) - Health insurer Cigna Corp (NYSE:CI)'s Evernorth unit would partner with Kaiser Permanente to help patients enrolled in some its rival's health plans gain access to doctors while traveling.
The agreement announced on Tuesday would make Evernorth the preferred external pharmacy partner of Kaiser for drugs to treat certain conditions.
Evernorth houses the pharmacy benefit management business Cigna acquired in its 2018 buyout of Express Scripts (NASDAQ:ESRX) as well as the company's specialty pharmacy business Accredo.
"We've set Evernorth up to be a partner of choice. And we have partner arrangements with entities that some might see as our competitors," Eric Palmer, CEO of Evernorth, said in an interview.
Pharmacy benefit managers serve as intermediaries between drug manufacturers, health insurance plans and pharmacies to negotiate prescription drug prices.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.